






**Figure 1**

**Figure 2**

**Figure 3**

**Figure 4**

**Figure 5**




Figure 6A





Figure 6B

**Figure 7A**





Figure 7B

**Figure 8A**







Figure 8B

**Figure 9**

**Figure 10A**

Compound (1): 0.5 nM (IC_{50})

**Figure 10B**

Compound	<i>in vitro</i> cell growth inhibition IC ₅₀ (nM)					P-gp susceptibility
	Esophageal cancer			Uterine sarcoma		
	OE21	OE33	TE-8	MES-SA	MES-SA/Dx5-Rx1	
Compound (f)	0.061	0.29	0.095	0.070	8.7	123

Figure 11




Figure 12




Figure 13




Figure 14



**FaDu
(SCCHN)**

Single dose
Day 6

Tenascin-C

Control

**Compound (1) at
180 µg/kg + cetuximab**



EDA-fibronectin





Figure 15




Figure 16




Figure 17




Figure 18